Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study
BACKGROUND Although the association between cytosine adenine guanine (CAG) repeat length and age at onset of Huntington's disease is well known, improved prediction of onset would be advantageous for clinical trial design and prognostic counselling. We compared various measures for tracking progression and predicting conversion to manifest Huntington's disease. METHODS In this prospective observational study, we assessed the ability of 40 measures in five domains (motor, cognitive, psychiatric, functional, and imaging) to predict time to motor diagnosis of Huntington's disease, accounting for CAG repeat length, age, and the interaction of CAG repeat length and age. Eligible participants were individuals from the PREDICT HD study (from 33 centres in six countries [USA, Canada, Germany, Australia, Spain, UK] with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15 item motor assessment of the Unified Huntington's Disease Rating Scale) Participants were followed up between September, 2002, and July, 2014. We used joint modelling of longitudinal and survival data to examine the extent to which baseline and change of measures analysed separately was predictive of CAG adjusted age at motor diagnosis. FINDINGS 1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5*1 years (SD 3*3, range 0*0 12*0) 225 (21% of these participants received a motor diagnosis of Huntington's disease during the study. 37 of 40 cross sectional and longitudinal clinical and imaging measures were significant predictors of motor diagnosis beyond CAG repeat length and age. The strongest predictors were in the motor, imaging, and cognitive domains: an increase of one SD in total motor score (motor domain) increased the risk of a motor diagnosis by 3*07 times (95% CI 2*26 4*16) a reduction of one SD in putamen volume (imaging domain) increased risk by 3*32 times (2*37 4*65) and a reduction of one SD in Stroop word score (cognitive domain) increased risk by 2*32 times (1*88 2*87) INTERPRETATION Prediction of diagnosis of Huntington's disease can be improved beyond that obtained by CAG repeat length and age alone. Such knowledge about potential predictors of manifest Huntington's disease should inform discussions about guidelines for diagnosis, prognosis, and counselling, and might be useful in guiding the selection of participants and outcome measures for clinical trials. FUNDING US National Institutes of Health, US National Institute of Neurological Disorders and Stroke, and CHDI Foundation.
The Lancet Neurology